Last reviewed · How we verify
NCT03121599
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
NA trial testing Diagnostic (18F-FLT PET/CT) in Essential Thrombocythemia in 3 participants. Terminated before completion.
15 October 2018
Quick facts
| Lead sponsor | Hamad Medical Corporation |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 3 |
| Start date | 11 June 2017 |
| Primary completion | 15 October 2018 |
| Estimated completion | 16 October 2018 |
| Sites | 1 location across Qatar |
Drugs / interventions tested
- Diagnostic (18F-FLT PET/CT)
Conditions studied
- Essential Thrombocythemia — all drugs for Essential Thrombocythemia →
- Primary Myelofibrosis, Fibrotic Stage — all drugs for Primary Myelofibrosis, Fibrotic Stage →
- Primary Myelofibrosis, Prefibrotic Stage — all drugs for Primary Myelofibrosis, Prefibrotic Stage →
- Polycythemia Vera — all drugs for Polycythemia Vera →
Sponsor
Hamad Medical Corporation — full company profile →
Who can join
Adults 14 to 18, any sex, with Essential Thrombocythemia or Primary Myelofibrosis, Fibrotic Stage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Main purpose of this project to study the uptake pattern of FLT-PET and it is value in assessing the malignant hematopoiesis in MPN within the pediatric age group, in terms of diagnosis, staging and monitoring response to therapy. As well as, evaluating FLT-PET as a novel non-invasive technique in cases with MPN and its role in comparison to the standard bone marrow biopsy with regard to disease diagnosis, assessment of disease activity, detection of transformation, monitoring of treatment response and grading of fibrosis.Furthermore, we aim to study the association of FLT-PET uptake patterns with different genetic makeup (JAK2, CALR positive, MPL, or Triple negative disease) or allele burden in cases of Pre-PMF with the ability of FLT-PET to differentiate between Pre-PMF and ET. Although MPNs are diseases of elderly, MPN is diagnosed in younger age groups in a considerable number of cases. Since most of the available data as well as current WHO classification criteria emphases on the "average" MPN patients who range in age between 55 and 65 years. Less consistent data are available in the groups of patients presenting below this median age, such as children and younger adults which we're planning to reveal.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review.
Greene BL, Marron JM. · · 2026 · PMID 41776770 · DOI 10.3322/caac.70075
Verify or expand the search:
- PubMed search for NCT03121599
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Essential Thrombocythemia
Currently open trials in the same condition.
- NCT06661915 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · Phase 2 · recruiting
- NCT06734637 — Efficacy and Safety of Peginterferon in ET and PV. · NA · recruiting
- NCT06456346 — Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) · Phase 3 · recruiting
- NCT06361641 — Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes · NA · recruiting
- NCT06378437 — A Study of GLB-001 in Patients With Myeloid Malignancies · Phase 1 · recruiting
Other Hamad Medical Corporation trials
Trials by the same sponsor.
- NCT07333209 — Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia · NA · recruiting
- NCT07270939 — Optimizing Enteral Nutrition Regimen for Critically Ill Patients · NA · not yet recruiting
- NCT07307508 — Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Ra · NA · recruiting
- NCT06622577 — The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric · NA · not yet recruiting
- NCT06887855 — Enhancing Post-Stroke Dysphagia Rehabilitation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03121599 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hamad Medical Corporation
- Last refreshed: 11 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03121599.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing